Hi, I’m Sanatan.
I build AI systems that help pharma and biotech teams move drugs from hypothesis to patient — faster and with better evidence.
Currently co-founder at Apxora, head of data science at AlphaMeld GmbH (formerly InveniAI GmbH), and CTO at Artixio — where I'm building QuriousRI. Based in Basel.
I build AI systems that move drugs from hypothesis to patient — platforms for target discovery, clinical trial intelligence, and regulatory automation.
- 18+Years Experience
- 5+Platforms Built
- 5Publications
- 2Patents
Tech stack
- Python
- TypeScript
- React
- Next.js
- PostgreSQL
- Neo4j
- AWS
- Docker
- PyTorch
- LangChain
Selected work
all workAlphaMeld® Operating System
Compresses hypothesis-to-insight cycles from months to weeks, varying by disease areaEnd-to-end AI stack combining a custom UI layer (Knowledge Graph, ChatAlphaMeld, Bioinformatics, Literature Analysis, AlphaClinMeld) with 12 ML models — including NER, RE, evidence scoring, digital-twin CT predictors and landscape assessment — running on PostgreSQL + Neo4j and self-hosted LLM APIs.
Discovery Navigator
Hypothesis landscaping compressed from weeks to hours, with traceable evidence at every stepGuided drug-discovery hypothesis-generation platform built on the AlphaMeld Knowledge Graph. Supports four starting points — disease-first, target-first, indication expansion, and combination therapy — through a step-by-step workflow (project → config → exploration → agent scoring → ranking → hypotheses). A project-aware Discovery Copilot accompanies every step. Multi-tenant SaaS with SSO, RBAC, and audit logging.
QuriousRI
Regulatory intelligence plus CTD dossier authoring and per-section market-entry gap assessment across Modules 2–5 and 12+ agencies — FDA, EMA, PMDA, NMPA, Health Canada, MHRA, Swissmedic, and moreSecure, role-based platform for pharma/biotech regulatory affairs teams to search, analyze, compare, and manage global drug and biologic approvals across pharmaceuticals, biologics, biosimilars, and generics. Beyond intelligence, it now carries two operational workstreams, both targeting Modules 2 through 5 of the CTD — Module 1 is deliberately out of scope, being country- and company-specific administrative content that does not transfer reliably between filings. CTD dossier preparation: AI-assisted authoring, with reproducibility tested and repeated so far on Module 2, the Quality Overall Summary, 3.2.P.1, and 3.2.P.3.3, and section coverage expanding across the remaining modules. Market-entry gap assessment: for a drug already approved in one market, the platform resolves, module by module and section by section, what a target market requires for that drug type and where those requirements diverge from the original filing. Underneath sit role-based dashboards, pathway and classification guides, a centralized guidelines library, expert Q&A, and LLM-powered document analysis.
Pipeline Alpha
Tracks ~10,000 clinical-trial drugs and AI-predicts the catalysts that move small-cap biotech stocksInvestment research platform for small/mid-cap NASDAQ biotechs where a single trial readout can move the stock 50%+. Syncs clinical-trial data (ClinicalTrials.gov, Clinical Navigator) with live stock and financials (Alpha Vantage), then runs LLM catalyst discovery and streaming AI predictions for upcoming readouts, PDUFA dates, partnerships, and conference events. Includes bulk catalyst briefings and an interactive research chat.
Work together
Advisory engagements, speaking invitations, and technical consulting for pharma, biotech, and consumer health.
Get in touch